|
|
News Breaks | | | | October 5, 2012 | | 07:57 EDT |  | SNSS | Sunesis valuation attractive, says Cowen
Cowen said the valuation of Sunesis is very attractive considering the company's worldwide ownership of of its oncology assets. The firm believes its AML drug will deserve premium pricing in both the US and Europe which will support its estimates of $700M+ revenue estimate. Shares are Outperform rated. | |
|
News For SNSS From The Last 14 Days Check below for free stories on SNSS the last two weeks. |
|
|
| May 9, 2013 | | 07:22 EDT |  | SNSS | Sunesis reports Q1 EPS (23c), consensus (20c)
Reports Q1 revenue $1.99M, consensus $750K. | |
|
|
|
|
|
|
